Omeros Corporation (OMER) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Omeros Corporation (OMER) has a cash flow conversion efficiency ratio of 0.229x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.51 Million) by net assets ($-63.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Omeros Corporation to measure how much of total assets are equity-financed.
Omeros Corporation - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Omeros Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Omeros Corporation (OMER) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Omeros Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omeros Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunyard System Engineering Co Ltd
SHG:600571
|
-0.078x |
|
PT Bukalapak.com
JK:BUKA
|
0.010x |
|
Jiangsu LiXing General Steel Ball Co Ltd
SHE:300421
|
0.009x |
|
Wilh Wilhelmsen Holding ASA B
OL:WWIB
|
-0.001x |
|
Chengdu Jafaantai Technology Co Ltd
SHE:300559
|
-0.020x |
|
Gold Royalty Corp.
NYSE MKT:GROY
|
0.004x |
|
Banco do Estado do Rio Grande do Sul S.A
SA:BRSR3
|
0.330x |
|
Chengdu Bright Eye Hospital Co. Ltd.
SHE:301239
|
N/A |
Annual Cash Flow Conversion Efficiency for Omeros Corporation (2007–2025)
The table below shows the annual cash flow conversion efficiency of Omeros Corporation from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see OMER market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-121.23 Million | $-116.09 Million | 0.958x | +17.52% |
| 2024-12-31 | $-182.61 Million | $-148.80 Million | 0.815x | +127.24% |
| 2023-12-31 | $-24.98 Million | $74.73 Million | -2.991x | -196.34% |
| 2022-12-31 | $85.68 Million | $-86.48 Million | -1.009x | +78.12% |
| 2021-12-31 | $23.78 Million | $-109.72 Million | -4.614x | -656.68% |
| 2020-12-31 | $-120.75 Million | $-100.09 Million | 0.829x | +50.42% |
| 2019-12-31 | $-109.02 Million | $-60.07 Million | 0.551x | +153.20% |
| 2018-12-31 | $100.16 Million | $-103.74 Million | -1.036x | -108.05% |
| 2017-12-31 | $-2.81 Million | $-36.23 Million | 12.874x | +836.02% |
| 2016-12-31 | $-37.45 Million | $-51.50 Million | 1.375x | -44.67% |
| 2015-12-31 | $-26.23 Million | $-65.21 Million | 2.486x | +82.66% |
| 2014-12-31 | $-42.65 Million | $-58.04 Million | 1.361x | -15.75% |
| 2013-12-31 | $-18.38 Million | $-29.70 Million | 1.615x | +903.15% |
| 2012-12-31 | $-214.58 Million | $-34.55 Million | 0.161x | -96.52% |
| 2011-12-31 | $-5.55 Million | $-25.67 Million | 4.622x | +752.34% |
| 2010-12-31 | $20.47 Million | $-14.50 Million | -0.708x | -60.65% |
| 2009-12-31 | $43.15 Million | $-19.03 Million | -0.441x | -304.36% |
| 2008-12-31 | $-91.17 Million | $-19.67 Million | 0.216x | +5.44% |
| 2007-12-31 | $-69.94 Million | $-14.31 Million | 0.205x | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more